65973-52-6

Basic information

• Product Name: Methyl 4,6-dichloronicotinate
• Synonyms: 4,6-Dichloronicotinic acid methyl ester;Methyl 4,6-dichloronicotinate;methyl 4,6-dichloropyridine-3-carboxylate;Methyl 4,6-dichloronicotinate 95+%;3-Pyridinecarboxylic acid, 4,6-dichloro-, Methyl ester;Methyl 4,6-dichloropyridine-3-carboxylate, 2,4-Dichloro-5-(methoxycarbonyl)pyridine;Methyl 4,6-dichloronicotinte;4,6-Dichloro-pyridin-3-carboxylic acid methyl ester
• CAS NO: 65973-52-6
• Molecular Formula: C₇H₅Cl₂NO₂
• Molecular Weight: 206.03
• Product Categories: Esters;Pyridines;Heterocyclic Compounds;Pyridine
• Mol File: 65973-52-6.mol

Chemical Properties

• Melting Point: 41-43°
• Boiling Point: 260 °C at 760 mmHg
• Flash Point: 111.1 °C
• Appearance: /Solid
• Density: 1.426 g/cm³
• Vapor Pressure: 0.0125mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.24±0.10(Predicted)
• CAS DataBase Reference: Methyl 4,6-dichloronicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4,6-dichloronicotinate(65973-52-6)
• EPA Substance Registry System: Methyl 4,6-dichloronicotinate(65973-52-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 65973-52-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 4,6-dichloronicotinate is used as a key intermediate in the synthesis of various pharmaceuticals for its unique reactivity and structural properties. It contributes to the development of new drugs by facilitating the creation of novel chemical entities with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, Methyl 4,6-dichloronicotinate is utilized as a building block for the production of pesticides and other crop protection agents. Its chemical properties allow for the design of effective compounds that can protect crops from pests and diseases, thereby enhancing agricultural productivity.
Used in Organic Intermediates:
Methyl 4,6-dichloronicotinate serves as an essential organic intermediate in the synthesis of a wide range of organic compounds. Its presence in the molecular structure can impart specific characteristics to the final product, making it a versatile component in organic chemistry and various chemical industries.

InChI:InChI=1/C7H5Cl2NO2/c1-12-7(11)4-3-10-6(9)2-5(4)8/h2-3H,1H3

Upstream product

• 93-60-7 methyl 3-pyridinecarboxylate 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 
• 73027-79-9 4,6-dichloro-nicotinic acid 
• 74-88-4 methyl iodide 
• 61043-19-4 2-[1-Ethoxy-meth-(Z)-ylidene]-3-oxo-pentanedioic acid dimethyl ester 
• 67-56-1 methanol 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 79398-27-9 1,6-dihydro-4-hydroxy-6-oxo-pyridine-3-carboxylic acid methyl ester 

Downstream Products

• 1386447-27-3 4-chloro-3-[(7-methoxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-3-carbonyl)-amino]-benzoic acid methyl ester 
• 1386447-28-4 7-methoxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-3-carboxylic acid (5-benzylcarbamoyl-2-chloro-phenyl)-amide 
• 1386447-75-1 [4-benzylamino-6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-methanol 
• 1386447-84-2 4-chloro-3-[(7-methoxy-2-oxo-1,2-dihydro-[1,6]naphthyridine-3-carbonyl)-amino]-benzoic acid 
• 1386447-54-6 3-{[7-(4-methyl-piperazin-1-yl)-2-oxo-1,2-dihydro-[1,6]naphthyridine-3-carbonyl]-amino}-benzoic acid methyl ester 
• 1256819-61-0 methyl 6-bromo-4-methoxy pyridine-3-carboxylate 
• 181819-65-8 (4,6-dimethoxypyidin-3-yl)methanol 

Relevant articles and documents

HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS

The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases

The discovery of 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid 13n (ceralifimod, ONO-4641), a sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5, is described. While it has been revealed that the modulation of the S1P1 receptor is an effective way to treat autoimmune diseases such as relapsing-remitting multiple sclerosis (RRMS), it was also reported that activation of the S1P3 receptor is implicated in some undesirable effects. We carried out a structure-activity relationship (SAR) study of hit compound 6 with an amino acid moiety in the hydrophilic head region. Following identification of a lead compound with a dihydronaphthalene central core by inducing conformational constraint, optimization of the lipophilic tail region led to the discovery of 13n as a clinical candidate that exhibited >30 000-fold selectivity for S1P1 over S1P3 and was potent in a peripheral lymphocyte lowering (PLL) test in mice (ED50 = 0.029 mg/kg, 24 h after oral dosing).

Preparation method of 6-chloro-4-hydroxypyridine-3-carbaldehyde

The invention provides a preparation method of 6-chloro-4-hydroxypyridine-3-carbaldehyde. The final product, namely, 6-chloro-4-hydroxypyridine-3-carbaldehyde, is obtained through six-step reactions including ring closure, chlorination, etherification, reduction, oxidation and hydrolysis. The synthesis method is simple and easy to operate, a synthesis route is provided for product synthesis, theoretical and experimental bases are provided for industrial production, three wastes polluting the environment are not produced in the synthesis process, and the preparation method is very environment-friendly and suitable for large-scale industrial production. The synthesized product has high purity and yield and the production cost is low.

A Facile Synthesis of New 4,6-Dichloropyridine Derivatives, Their Biological Evaluation for Antimicrobial and Antioxidant Activity, and Docking Studies

A facile synthesis of new 4,6-dichloropyridine derivatives 5(a–f), 6(a–c), and 7(a–c) were synthesized using both conventional heating and solvent-free microwave irradiation techniques. The results revealed that the latter method is superior to the conventional heating method. The easy work-up of the products, rapid reaction, and mild conditions are noticeable features of this protocol. Structural elucidation of the synthesized compounds was made on the basis of various spectroscopic methods. The synthesized compounds were evaluated for their in vitro antimicrobial activity (minimum inhibitory concentration; MIC) against various microbial strains using the agar well-diffusion method. Among the compounds, 5c showed best antimicrobial activity against most of the employed strains, especially against Staphylococcus aureus, Escherichia coli, Rhizopus arrhizus, and Candida albicans. Compounds 5a, 6a, 6c, 7a, and 7c showed significant antioxidant activity when compared to the other compounds. In addition to this, theoretical docking studies were performed for the highly potent compounds 5a, 6a, 6c, 7a, and 7c against three different drug targets belonging to the oxidoreductase family, and the results were found to be highly satisfactory.

PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

Structure-based design of substituted piperidines as a new class of highly efficacious oral direct renin inhibitors

A cis-configured 3,5-disubstituted piperidine direct renin inhibitor, (syn,rac)-1, was discovered as a high-throughput screening hit from a target-family tailored library. Optimization of both the prime and the nonprime site residues flanking the central piperidine transition-state surrogate resulted in analogues with improved potency and pharmacokinetic (PK) properties, culminating in the identification of the 4-hydroxy-3,5-substituted piperidine 31. This compound showed high in vitro potency toward human renin with excellent off-target selectivity, 60% oral bioavailability in rat, and dose-dependent blood pressure lowering effects in the double-transgenic rat model.

AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS

This invention relates to novel compounds of formula (I), which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

1,6- AND 1,8-NAPHTHYRIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I)

INHIBITORS OF MEK

This invention concerns to N-(2-aylamino) aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.